[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
作者信息
Liu He, Chen Xiao-Guang
出版信息
Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):561-3.
PMID:17236546
Abstract
摘要
相似文献
1
[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):561-3.
2
Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
J Clin Exp Hematop. 2012;52(2):145-7. doi: 10.3960/jslrt.52.145.
3
Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Clin Adv Hematol Oncol. 2011 Oct;9(10):734-45.
4
10 years of progress in chronic myelogenous leukemia.
J Natl Compr Canc Netw. 2012 Sep;10(9):1049-53. doi: 10.6004/jnccn.2012.0110.
5
Two new agents effective in Gleevec-resistant CML.
Cancer Biol Ther. 2004 Dec;3(12):1198-9.
6
As leukemia options grow, drugs jockey to be first-line therapies.
Nat Med. 2013 Jan;19(1):7. doi: 10.1038/nm0113-7.
7
[State of the art in the treatment of chronic leukemias].
Rinsho Ketsueki. 2006 Apr;47(4):278-86.
8
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Am J Hematol. 2009 Apr;84(4):256-7. doi: 10.1002/ajh.21366.
9
Loss of response to imatinib: mechanisms and management.
Hematology Am Soc Hematol Educ Program. 2005:183-7. doi: 10.1182/asheducation-2005.1.183.
10
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Expert Opin Investig Drugs. 2007 May;16(5):679-87. doi: 10.1517/13543784.16.5.679.
Zotero 插件